NERM
RMD icon

New England Research & Management’s ResMed RMD Stock Holding History

New England Research & Management’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-2,350
Closed -$244K – 179
2019
Q1 		$244K Buy
+2,350
New +$243K 0.16% 147

Other funds holding RMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

New England Research & Management's RMD Position: Q2 2019 in Review

New England Research & Management sold out of ResMed (RMD) in Q2 2019, closing a stake of 2,350 shares — an estimated $244K sold.

New England Research & Management first reported a position in RMD in Q1 2019 and held it in 1 quarter. The position peaked at $244K in Q1 2019. 485 funds tracked by Wall St. Rank hold RMD as of Q2 2019.

  • New England Research & Management reported no remaining ResMed position as of Q2 2019 after selling out during the quarter.
  • New England Research & Management sold 2,350 ResMed shares in Q2 2019, an estimated $244K.
  • New England Research & Management first reported a position in ResMed in Q1 2019 and held it in 1 quarter.
  • New England Research & Management's ResMed position peaked at $244K in Q1 2019.
  • 485 funds tracked by Wall St. Rank held ResMed as of Q2 2019.

Based on New England Research & Management's 13F filing for Q2 2019, filed 9 Jul 2019.